Blood glutathione as a surrogate marker of cancer tissue glutathione S-transferase activity in non-small cell lung cancer and squamous cell carcinoma of the head and neck

E. Ferruzzi, R. Franceschini, G. Cazzolato, C. Geroni, C. Fowst, U. Pastorino, N. Tradati, J. Tursi, R. Dittadi, M. Gion

Research output: Contribution to journalArticle

Abstract

The identification of markers predicting the response to therapy is of the utmost importance in oncology. Several authors have suggested that increased levels of glutathione (GSH) and glutathione S-transferase (GST) activity might be meaningful predictors of poor responsiveness to chemotherapy in several human cancers, but the biological assays have not been standardised and published studies show conflicting evidence. The aim of the present study was to select a validated panel of tests to assess the GST/GSH system in a clinical setting. Matched blood and tissue samples (normal and malignant) from 52 cancer patients with either non-small cell lung cancer (NSCLC) or head and neck squamous cell carcinoma (SCCHN) were investigated. GSH levels and GST activity were higher in cancer tissues than in matched normal tissues in both malignancies. The difference was statistically significant in NSCLC (P=0.0004 and P=0.0002, for GSH and GST, respectively) and borderline in SCCHN (P=0.03 and P=0.02, for GSH and GST, respectively). Moreover a strong correlation was found between the GSH level in whole blood and GST activity in cancer tissue in both malignancies (P=0.003, r=0.53 in NSCLC, P

Original languageEnglish
Pages (from-to)1019-1029
Number of pages11
JournalEuropean Journal of Cancer
Volume39
Issue number7
DOIs
Publication statusPublished - May 2003

Fingerprint

Glutathione Transferase
Non-Small Cell Lung Carcinoma
Glutathione
Biomarkers
Neoplasms
Head and Neck Neoplasms
Biological Assay
Carcinoma, squamous cell of head and neck
Drug Therapy

Keywords

  • Glutathione
  • Glutathione S-transferase
  • Head and neck squamous cell carcinoma (SCCHN)
  • Non-small cell lung cancer (NSCLC)
  • Resistance to chemotherapy
  • Surrogate markers

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Blood glutathione as a surrogate marker of cancer tissue glutathione S-transferase activity in non-small cell lung cancer and squamous cell carcinoma of the head and neck. / Ferruzzi, E.; Franceschini, R.; Cazzolato, G.; Geroni, C.; Fowst, C.; Pastorino, U.; Tradati, N.; Tursi, J.; Dittadi, R.; Gion, M.

In: European Journal of Cancer, Vol. 39, No. 7, 05.2003, p. 1019-1029.

Research output: Contribution to journalArticle

Ferruzzi, E. ; Franceschini, R. ; Cazzolato, G. ; Geroni, C. ; Fowst, C. ; Pastorino, U. ; Tradati, N. ; Tursi, J. ; Dittadi, R. ; Gion, M. / Blood glutathione as a surrogate marker of cancer tissue glutathione S-transferase activity in non-small cell lung cancer and squamous cell carcinoma of the head and neck. In: European Journal of Cancer. 2003 ; Vol. 39, No. 7. pp. 1019-1029.
@article{30cd92d5e6b5469085dbe581d1892930,
title = "Blood glutathione as a surrogate marker of cancer tissue glutathione S-transferase activity in non-small cell lung cancer and squamous cell carcinoma of the head and neck",
abstract = "The identification of markers predicting the response to therapy is of the utmost importance in oncology. Several authors have suggested that increased levels of glutathione (GSH) and glutathione S-transferase (GST) activity might be meaningful predictors of poor responsiveness to chemotherapy in several human cancers, but the biological assays have not been standardised and published studies show conflicting evidence. The aim of the present study was to select a validated panel of tests to assess the GST/GSH system in a clinical setting. Matched blood and tissue samples (normal and malignant) from 52 cancer patients with either non-small cell lung cancer (NSCLC) or head and neck squamous cell carcinoma (SCCHN) were investigated. GSH levels and GST activity were higher in cancer tissues than in matched normal tissues in both malignancies. The difference was statistically significant in NSCLC (P=0.0004 and P=0.0002, for GSH and GST, respectively) and borderline in SCCHN (P=0.03 and P=0.02, for GSH and GST, respectively). Moreover a strong correlation was found between the GSH level in whole blood and GST activity in cancer tissue in both malignancies (P=0.003, r=0.53 in NSCLC, P",
keywords = "Glutathione, Glutathione S-transferase, Head and neck squamous cell carcinoma (SCCHN), Non-small cell lung cancer (NSCLC), Resistance to chemotherapy, Surrogate markers",
author = "E. Ferruzzi and R. Franceschini and G. Cazzolato and C. Geroni and C. Fowst and U. Pastorino and N. Tradati and J. Tursi and R. Dittadi and M. Gion",
year = "2003",
month = "5",
doi = "10.1016/S0959-8049(03)00122-9",
language = "English",
volume = "39",
pages = "1019--1029",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "7",

}

TY - JOUR

T1 - Blood glutathione as a surrogate marker of cancer tissue glutathione S-transferase activity in non-small cell lung cancer and squamous cell carcinoma of the head and neck

AU - Ferruzzi, E.

AU - Franceschini, R.

AU - Cazzolato, G.

AU - Geroni, C.

AU - Fowst, C.

AU - Pastorino, U.

AU - Tradati, N.

AU - Tursi, J.

AU - Dittadi, R.

AU - Gion, M.

PY - 2003/5

Y1 - 2003/5

N2 - The identification of markers predicting the response to therapy is of the utmost importance in oncology. Several authors have suggested that increased levels of glutathione (GSH) and glutathione S-transferase (GST) activity might be meaningful predictors of poor responsiveness to chemotherapy in several human cancers, but the biological assays have not been standardised and published studies show conflicting evidence. The aim of the present study was to select a validated panel of tests to assess the GST/GSH system in a clinical setting. Matched blood and tissue samples (normal and malignant) from 52 cancer patients with either non-small cell lung cancer (NSCLC) or head and neck squamous cell carcinoma (SCCHN) were investigated. GSH levels and GST activity were higher in cancer tissues than in matched normal tissues in both malignancies. The difference was statistically significant in NSCLC (P=0.0004 and P=0.0002, for GSH and GST, respectively) and borderline in SCCHN (P=0.03 and P=0.02, for GSH and GST, respectively). Moreover a strong correlation was found between the GSH level in whole blood and GST activity in cancer tissue in both malignancies (P=0.003, r=0.53 in NSCLC, P

AB - The identification of markers predicting the response to therapy is of the utmost importance in oncology. Several authors have suggested that increased levels of glutathione (GSH) and glutathione S-transferase (GST) activity might be meaningful predictors of poor responsiveness to chemotherapy in several human cancers, but the biological assays have not been standardised and published studies show conflicting evidence. The aim of the present study was to select a validated panel of tests to assess the GST/GSH system in a clinical setting. Matched blood and tissue samples (normal and malignant) from 52 cancer patients with either non-small cell lung cancer (NSCLC) or head and neck squamous cell carcinoma (SCCHN) were investigated. GSH levels and GST activity were higher in cancer tissues than in matched normal tissues in both malignancies. The difference was statistically significant in NSCLC (P=0.0004 and P=0.0002, for GSH and GST, respectively) and borderline in SCCHN (P=0.03 and P=0.02, for GSH and GST, respectively). Moreover a strong correlation was found between the GSH level in whole blood and GST activity in cancer tissue in both malignancies (P=0.003, r=0.53 in NSCLC, P

KW - Glutathione

KW - Glutathione S-transferase

KW - Head and neck squamous cell carcinoma (SCCHN)

KW - Non-small cell lung cancer (NSCLC)

KW - Resistance to chemotherapy

KW - Surrogate markers

UR - http://www.scopus.com/inward/record.url?scp=0037403571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037403571&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(03)00122-9

DO - 10.1016/S0959-8049(03)00122-9

M3 - Article

C2 - 12706373

AN - SCOPUS:0037403571

VL - 39

SP - 1019

EP - 1029

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 7

ER -